Atrophy of multiple systems
Conditions
Interventions
Experimental Group:Procedure and Stimulation Protocol
Pre-operative Assessment
Prior to enrollment, all patients underwent standard pre-operative assessment using standardized scales, which did not i
Sponsors
Department of Neurology, Xuanwu Hospital
Eligibility
Sex/Gender
All
Age
30 Years to 75 Years
Inclusion criteria
Inclusion criteria: Probable MSA (Probable MSA) that conforms to the 2022 revised version of the International Society for Dyskinesia (MDS) or the 2008 Gilman consensus diagnostic criteria, with gait disorder as the chief complaint; Subtype definition: Clearly diagnosed as MSA-P type (Parkinson's type) or MSA-C type (cerebellar type); 1.The disease course is 1 to 5 years; 2. Gait disorder persists for >=6 months, and there is insufficient response to conventional treatment (levodopa test, rehabilitation training) (UPDRS-III walking project score >=3 points or SARA gait score >=4 points); 3. No complete loss of walking ability (no need to rely on a wheelchair, able to walk independently or with the assistance of a single crutch for >=10 meters); 4. Age: 30 to 75 years old, gender not limited, and signed informed consent form; 5. Not participated in other interventional clinical trials and committed to completing at least 12 months of follow-up;
Exclusion criteria
Exclusion criteria: 1. Severe cardiopulmonary dysfunction (NYHA grade III-IV, COPD GOLD stage 3-4), severe cognitive impairment (MMSE=17 points); 2. There are contraindications for SCS implantation: coagulation dysfunction (INR>1.5), immunosuppressive status, and local skin infection; 3. A pacemaker, defibrillator or other electronic medical device has been implanted in the body; 4. Previously received spinal cord surgery or deep brain stimulation (DBS) treatment; 5. Have used experimental neuroprotective agents (such as riniazole, minocycline) within the past three months; The dosage of dopaminergic drugs is unstable (adjusted by >=30% within the past month). 6. History of alcohol or drug dependence, etc.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Gait scale score; | — |
Secondary
| Measure | Time frame |
|---|---|
| Gait Acquisition;Quality of life;Cognitive function;Sleep disorder; | — |
Countries
China
Contacts
Public ContactLin Hua;Zhang Yuqing
Xuanwu Hospital, Capital Medical University
Outcome results
None listed